Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
$5.41
-$0.42(-9.17%)
At close: 4:00 PM EST
$5.41
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $8.90
Previous CloseN/A
Volume477.34K
Average Volume (3M)4.17M
Market Cap
$519.37M
Enterprise Value$368.62M
Total Cash (Recent Filing)$185.94M
Total Debt (Recent Filing)$35.18M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,517,044
10 Day Avg. Volume2,496,762
30 Day Avg. Volume4,172,238
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$22.09Price Target Upside308.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityPhase 3 confirmatory trials met primary endpoints and demonstrated rapid, clinically meaningful and durable antidepressant effects, with an optional second dose increasing the share of patients achieving remission.
Commercial And Reimbursement ReadinessEstablished procedural coding and the ability to deliver COMP360 within existing interventional psychiatry clinics support smoother reimbursement discussions and scalable commercial adoption without major facility changes.
Regulatory Engagement And PathwayCollaborative engagement with the FDA's psychiatry division and the potential for a rolling submission under an expedited pathway could accelerate regulatory review and allow preparatory site build-out before formal approval.
Bears Say
Control Arm Activity And Effect Size UncertaintyClinical activity observed in a low-dose control and a smaller-than-expected treatment effect compared with earlier trials could complicate regulatory interpretation and temper investor confidence.
Data And Regulatory Risk From Limited DatasetsReliance on relatively small clinical datasets increases development and regulatory risk and may leave efficacy interpretations vulnerable to differing regulator views.
Funding And Dilution RiskHigh cash burn and a limited cash runway create a material funding and dilution risk that could force equity raises before commercialization is self-sustaining.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.25 and its highest was $8.90 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $519.37M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were COMPASS Pathways’s earnings last quarter?
Currently, no data Available
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 113,517,044 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.09 (308.32% Upside)
$22.09 (308.32% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 56.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.46%
12-Months-Change
Fundamentals
Return on Equity
-172.50%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials, regulatory interactions, and launch preparations. While there was a decrease in cash reserves, the company maintains a strong cash position with a runway into 2027.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$22.09
▲(308.32% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.27% Insiders
0.75% Mutual Funds
33.15% Other Institutional Investors
61.86% Public Companies and Individual Investors